口服避孕药使用时长与卵巢、子宫内膜、乳腺及结直肠癌关联的效应修饰
基于NIH-AARP前瞻性队列(1995-1996年入组,随访至2011年),纳入至少10万名报告口服避孕药使用的女性,分析使用时长与四种癌症风险的关联是否受吸烟、饮酒、BMI和体力活动影响。长期使用与卵巢癌风险降低一致相关(≥10年HR 0.60),子宫内膜癌风险降低在吸烟、肥胖或极少运动者中更显著,乳腺癌和结直肠癌关联基本为零。
要点
- 长期口服避孕药使用与卵巢癌风险降低一致相关,不受生活方式因素影响。
- 子宫内膜癌风险降低在吸烟、肥胖或极少运动的长期使用者中更显著。
- 口服避孕药使用与乳腺癌和结直肠癌风险基本无关联。
核心结论
- 长期口服避孕药使用与卵巢癌风险降低一致相关,且不受可改变生活方式因素影响。
- 子宫内膜癌风险降低在吸烟、肥胖或极少运动的长期使用者中更显著。
- 口服避孕药使用与乳腺癌和结直肠癌风险基本无关联。
研究设计与样本
- 前瞻性NIH-AARP饮食与健康研究,1995-1996年入组,随访至2011年。
- 从6个州和2个大都市区基于人群招募AARP成员。
- 数据分析于2016年9月至2017年4月进行。
主要发现
- 长期使用口服避孕药的吸烟者子宫内膜癌风险降低最显著(HR 0.47,95%CI 0.25-0.88)。
- 长期使用口服避孕药的肥胖BMI者子宫内膜癌风险降低(HR 0.36,95%CI 0.25-0.52)。
- 长期使用口服避孕药的极少运动者子宫内膜癌风险降低(HR 0.40,95%CI 0.29-0.56)。
临床怎么用
- 长期口服避孕药使用与卵巢癌风险降低一致相关,可视为化学预防的潜在有益因素。
- 对于吸烟、肥胖或极少运动的女性,长期口服避孕药使用与子宫内膜癌风险降低更显著。
- 口服避孕药使用与乳腺癌和结直肠癌风险基本无关联,不改变相关筛查建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although oral contraceptive (OC) use is common, the influence of OC use on carcinogenesis is not fully understood. A recent Agency for Healthcare Research and Quality report identified a need to understand the consistency of OC use and cancer associations across subpopulations, including smokers and obese women. OBJECTIVE: To determine whether associations between duration of OC use and risk of specific cancers were modified by lifestyle characteristics. DESIGN, SETTING, AND PARTICIPANTS: The prospective NIH-AARP Diet and Health Study (enrolled 1995-1996, followed until 2011), with population-based recruitment of AARP members in 6 states and 2 metropolitan areas. All analyses included at least 100 000 women who reported OC use at enrollment. We identified 1241 ovarian, 2337 endometrial, 11 114 breast, and 3507 colorectal cancer cases during follow-up. Data analysis was performed between September 2016 and April 2017. EXPOSURES: Duration of OC use (never or <1 year [reference], 1-4, 5-9, or ≥10 years). MAIN OUTCOMES AND MEASURES: Development of ovarian, endometrial, breast, and colorectal cancers. We examined effect modification by modifiable lifestyle characteristics: cigarette smoking, alcohol consumption, body mass index (BMI), and physical activity. We used Cox models adjusted for age, race, age at menarche, and the modifiers of interest. RESULTS: The analytic population was aged 50 to 71 years (median, 62 years) at enrollment and largely white (91%) and postmenopausal (96%). For ovarian cancer, OC use-associated risk reductions strengthened with duration of use (long-term OC use [≥10 years] HR, 0.60; 95% CI, 0.47-0.76; P < .001 for trend) and were similar across modifiable lifestyle factors. Risk reductions for endometrial cancer strengthened with duration of use (long-term OC use HR, 0.66; 95% CI, 0.56-0.78; P < .001 for trend); the most pronounced reductions were among long-term OC users who were smokers (HR, 0.47; 95% CI, 0.25-0.88), had obese BMIs (0.36; 95% CI, 0.25-0.52), and who exercised rarely (HR, 0.40; 95% CI, 0.29-0.56). Associations between OC use and breast and colorectal cancers were predominantly null. CONCLUSIONS AND RELEVANCE: Long-term OC use is consistently associated with reduced ovarian cancer risk across lifestyle factors. We observed the greatest risk reductions for endometrial cancer among women at risk for chronic diseases (ie, smokers, obese BMI). Oral contraceptive use may be beneficial for chemoprevention for a range of women with differing baseline cancer risks.
引用
- Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol. 2018. PMID: 29346467. doi:10.1001/jamaoncol.2017.4942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。